二叶式主动脉瓣患者经导管主动脉瓣置换术结局:STS/ACC TVT注册报告
基于STS/ACC TVT注册2011年11月至2018年11月数据,比较二叶式与三叶式主动脉瓣狭窄患者TAVR结局。二叶式占3.2%(5412例),使用当代器械时器械成功率96.3% vs 97.4%(P=0.07),残留中重度主动脉瓣反流2.7% vs 2.1%(P<0.001);Medicare队列1年调整死亡风险HR 0.88(95%CI 0.78-0.99),卒中风险无差异(HR 1.14,95%CI 0.94-1.39)。
要点
- 二叶式主动脉瓣狭窄患者占TAVR的3.2%,使用当代器械后器械成功率提高至96.3%。
- 当代器械下二叶式与三叶式器械成功率相近(96.3% vs 97.4%,P=0.07)。
- 二叶式患者1年调整死亡风险低于三叶式(HR 0.88,95%CI 0.78-0.99)。
核心结论
- 使用当代器械时,二叶式主动脉瓣狭窄患者TAVR的术中、术后及1年结局与三叶式患者相当。
- 新型器械下TAVR是二叶式主动脉瓣疾病患者的可行治疗选择。
研究设计与样本
- 其中二叶式主动脉瓣患者5412例(3.2%),包括3705例使用当代器械(Sapien 3和Evolut R)。
- 通过Medicare行政索赔数据评估≥65岁患者1年死亡和卒中。
主要发现
- 二叶式患者较三叶式患者更年轻且STS预测死亡风险评分更低。
- 二叶式患者使用当代器械较旧代器械器械成功率提高(93.5 vs 96.3,P=0.001),2+主动脉瓣反流发生率下降(14.0% vs 2.7%,P<0.001)。
- 当代器械下二叶式与三叶式器械成功率分别为96.3%与97.4%(P=0.07),残留中重度主动脉瓣反流分别为2.7%与2.1%(P<0.001)。
- Medicare联动队列中二叶式较三叶式1年调整死亡风险更低(HR 0.88,95%CI 0.78-0.99),1年调整卒中风险无差异(HR 1.14,95%CI 0.94-1.39)。
临床怎么用
- 对于二叶式主动脉瓣狭窄患者,使用当代TAVR器械(Sapien 3和Evolut R)可获得与三叶式患者相当的结局。
- 二叶式患者TAVR术后残留中重度主动脉瓣反流发生率略高,需关注术后瓣膜性能。
局限性
- 为注册研究,非随机对照,可能存在选择偏倚和未测量混杂因素。
- 1年死亡和卒中数据仅来自Medicare联动队列(≥65岁),可能不适用于年轻患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with bicuspid aortic valve (AV) stenosis were excluded from the pivotal evaluations of transcatheter AV replacement (TAVR) devices. We sought to evaluate the outcomes of TAVR in patients with bicuspid AV stenosis in comparison with those with tricuspid AV stenosis. METHODS: We used data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (November 2011 through November 2018) to determine device success, procedural outcomes, post-TAVR valve performance, and in-hospital clinical outcomes (mortality, stroke, and major bleeding) according to valve morphology (bicuspid versus tricuspid). Results were stratified by older and current (Sapien 3 and Evolut R) generation valve prostheses. Medicare administrative claims were used to evaluate mortality and stroke to 1 year among eligible individuals (≥65 years). RESULTS: After exclusions, there were 170 959 eligible procedures at 593 sites during the specified interval. Of these, 5412 TAVR procedures (3.2%) were performed in patients with bicuspid AV, including 3705 with current-generation devices. In comparison with patients with tricuspid valves, patients with bicuspid AV were younger and had a lower Society of Thoracic Surgeons Predicted Risk of Operative Mortality score. When current-generation devices were used to treat patients with bicuspid AV, device success increased (93.5 versus 96.3; P=0.001) and the incidence of 2+ aortic insufficiency declined (14.0% versus 2.7%; P<0.001) in comparison with older-generation devices. With current-generation devices, device success was slightly lower in the bicuspid (versus tricuspid) AV group (96.3% in bicuspid versus 97.4% in tricuspid, P=0.07), with a slightly higher incidence of residual moderate or severe aortic insufficiency among patients with bicuspid AV (2.7% versus 2.1%; P<0.001). A lower 1-year adjusted risk of mortality (hazard ratio, 0.88 [95% CI, 0.78-0.99]) was observed for patients with bicuspid AV versus patients with tricuspid AV in the Medicare-linked cohort, whereas no difference was observed in the 1-year adjusted risk of stroke (hazard ratio, 1.14 [95% CI, 0.94-1.39]). CONCLUSIONS: Using current-generation devices, procedural, postprocedural, and 1-year outcomes were comparable following TAVR for bicuspid AV versus tricuspid AV disease. With newer-generation devices, TAVR is a viable treatment option for patients with bicuspid AV disease.
引用
- Halim SA, Edwards FH, Dai D, et al. Outcomes of Transcatheter Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Disease: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation. 2020. PMID: 32098500. doi:10.1161/CIRCULATIONAHA.119.040333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。